Syros Pharmaceuticals (SYRS)
(Delayed Data from NSDQ)
$2.00 USD
+0.02 (1.01%)
Updated Sep 17, 2024 04:00 PM ET
After-Market: $2.00 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for Syros Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -164.57 | -94.65 | -86.56 | -84.04 | -75.44 |
Depreciation/Amortization & Depletion | 2.83 | 3.66 | 3.72 | 3.32 | 2.72 |
Net Change from Assets/Liabilities | 5.06 | -5.52 | -10.60 | 12.09 | 3.75 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 46.99 | -26.55 | -6.10 | 11.27 | 8.71 |
Net Cash From Operating Activities | -109.71 | -123.07 | -99.54 | -57.36 | -60.25 |
Property & Equipment | 1.29 | -1.24 | -1.25 | -3.34 | -12.53 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 36.05 | 68.43 | -51.41 | 50.00 | 0.79 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 37.34 | 67.19 | -52.65 | 46.66 | -11.73 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 43.53 | 119.98 | 70.82 | 103.78 | 66.20 |
Issuance (Repayment) of Debt | -0.07 | -0.29 | -0.27 | 39.38 | -0.21 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | 0.00 | 11.36 | -0.04 | -0.21 | 0.00 |
Net Cash from Financing Activities | 43.46 | 131.05 | 70.51 | 142.95 | 65.99 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -28.91 | 75.17 | -81.68 | 132.25 | -6.00 |
Cash at Beginning of Period | 170.55 | 95.39 | 177.07 | 44.82 | 50.81 |
Cash at End of Period | 141.65 | 170.55 | 95.39 | 177.07 | 44.82 |
Diluted Net EPS | -5.81 | -7.49 | -13.80 | -18.20 | -18.80 |
Fiscal Year End for Syros Pharmaceuticals, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -27.04 | -3.71 | -164.57 | -100.19 | -60.05 |
Depreciation/Amortization & Depletion | 0.94 | 0.49 | 2.83 | 2.32 | 1.57 |
Net Change from Assets/Liabilities | -6.79 | -2.86 | 5.06 | -1.20 | 0.59 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | -27.88 | -25.01 | 46.99 | 7.92 | -1.40 |
Net Cash From Operating Activities | -60.77 | -31.10 | -109.71 | -91.15 | -59.29 |
Property & Equipment | 0.13 | 0.03 | 1.29 | -0.23 | -0.23 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 0.30 | -24.67 | 36.05 | 36.05 | 7.41 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 0.43 | -24.64 | 37.34 | 35.82 | 7.18 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 0.12 | 0.00 | 43.53 | 0.14 | 0.14 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | -0.07 | -0.06 | -0.06 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.34 | -0.27 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | -0.22 | -0.27 | 43.46 | 0.08 | 0.09 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | -60.56 | -56.00 | -28.91 | -55.25 | -52.03 |
Cash at Beginning of Period | 141.65 | 141.65 | 170.55 | 170.55 | 170.55 |
Cash at End of Period | 81.08 | 85.64 | 141.65 | 115.31 | 118.53 |
Diluted Net EPS | -0.59 | -0.10 | -2.23 | -1.43 | -1.30 |